Clinically accurate assessment and grading of ototoxicity

Laryngoscope

Volumn 121, Issue 12, 2011, Pages 2649-2657

  Chang, Kay W ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cisplatin; ototoxicity

Indexed keywords

CISPLATIN;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; DEVICE; HUMAN; MAJOR CLINICAL STUDY; OTOTOXICITY; PRIORITY JOURNAL; PURE TONE AUDIOMETRY; RETROSPECTIVE STUDY; TREATMENT INDICATION;

ADOLESCENT; ADULT; AUDIOMETRY, PURE-TONE; CHILD; CHILD, PRESCHOOL; CISPLATIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EVOKED POTENTIALS, AUDITORY, BRAIN STEM; FEMALE; FOLLOW-UP STUDIES; HEARING LOSS; HEARING LOSS, SENSORINEURAL; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 82155166492     PISSN: 0023852X     EISSN: 15314995     Source Type: Journal    
DOI: 10.1002/lary.22376     Document Type: Article

References (41)

1. Neuwelt EA, Brock P,. Critical need for international consensus on ototoxicity assessment criteria. J Clin Oncol 2010; 28: 1630-1632.
2. Chang KW, Chinosornvatana N,. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol 2010; 28: 1788-1795.
3. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J,. Cisplatin ototoxicity in children: a practical grading system. Med Pediatr Oncol 1991; 19: 295-300.
4. National Cancer Institute. Common terminology criteria for adverse events, version 3.0 and 4.0. Available at:. Accessed December 15, 2010.
5. Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer 2005; 104: 841-847. (Pubitemid 41113686)
6. Katzenstein HM, Chang KW, Krailo M, et al. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma: a report of the Intergroup Hepatoblastoma Study P9645 as a part of the Children's Oncology Group. Cancer 2009; 115: 5828-5835.
7. Knight KR, Kraemer DF, Neuwelt EA,. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2005; 23: 8588-8596. (Pubitemid 46211500)
8. Zuur CL, Simis YJ, Lansdaal PE, et al. Ototoxicity in a randomized phase III trial of intra-arterial compared with intravenous cisplatin chemoradiation in patients with locally advanced head and neck cancer. J Clin Oncol 2007; 25: 3759-3765. (Pubitemid 47372618)
9. Gupta AA, Capra M, Papaioannou V, et al. Low incidence of ototoxicity with continuous infusion of cisplatin in the treatment of pediatric germ cell tumors. J Pediatr Hematol Oncol 2006; 28: 91-94.
10. Kushner BH, Budnick A, Kramer K, Modak S, Cheung NK,. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer 2006; 107: 417-422. (Pubitemid 44036572)
11. Dreschler WA, van der Hulst RJ, Tange RA, Urbanus NA,. The role of high frequency audiometry in early detection of ototoxicity. Audiology 1985; 24: 387-395. (Pubitemid 16234603)
12. Fausti SA, Henry JA, Schaffer HI, et al. High-frequency monitoring for early detection of cisplatin ototoxicity. Arch Otolaryngol Head Neck Surg 1993; 119: 661-666. (Pubitemid 23161975)
13. Knight KR, Kraemer DF, Winter C, Neuwelt EA,. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions. J Clin Oncol 2007; 25: 1190-1195. (Pubitemid 46640564)
14. Van der Hulst RJ,. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol Laryngol 1988; 97 (2 pt 1): 133-137.
15. Komune S, Asakuma S, Snow JB Jr,. Pathophysiology of the ototoxicity of cis-diamminedichloroplatinum. Otolaryngol Head Neck Surg 1981; 89: 275-282. (Pubitemid 11090690)
16. Estrem SA, Babin RW, Ryu JH, Moore KC,. Cis-diamminedichloroplatinum (II) ototoxicity in the guinea pig. Otolaryngol Head Neck Surg 1981; 89: 638-645. (Pubitemid 12201093)
17. Moroso MJ, Blair RL,. A review of cis-platinum ototoxicity. J Otolaryngol 1983; 12: 365-369. (Pubitemid 14223103)
18. Strauss M, Towfighi J, Lord S, Lipton A, Harvey HA, Brown B,. Cisplatin ototoxicity: Clinical experience and temporal bone histopathology. Laryngoscope 1983; 93: 1554-1559. (Pubitemid 14204680)
19. French NR, Steinberg JC,. Factors governing the intelligibility of speech sounds. J Acoust Soc Am 1947; 19: 90-119.
20. Stelmachowicz PG, Pittman AL, Hoover BM, Lewis DE, Moeller MP,. The importance of high frequency audibility in the speech and language development of children with hearing loss. Arch Otolaryngol Head Neck Surg 2004; 103: 556-562. (Pubitemid 38609664)
21. Stelmachowicz PG, Pittman AL, Hoover BM, Lewis DE,. Novel-word learning in children with normal hearing and hearing loss. Ear Hear 2004; 25: 47-56. (Pubitemid 38182604)
22. Pittman AL, Lewis DE, Hoover BM, Stelmachowicz PG,. Rapid word-learning in normal-hearing and hearing-impaired children: effects of age, receptive vocabulary, and high-frequency amplification. Ear Hear 2005; 26: 619-629. (Pubitemid 44378677)
23. Fausti SA, Frey RH, Henry JA, Olson DJ, Schaffer HI,. Early detection of ototoxicity using high frequency, tone- burst evoked auditory brainstem responses. J Am Acad Audiol 1992; 3: 397-404.
24. Arnold DJ, Lonsbury-Martin BL, Martin GK,. High-frequency hearing influences distortion product otoacoustic emissions. Arch Otolaryngol Head Neck Surg 1999; 125: 215-222. (Pubitemid 29085271)
25. Ress BD, Sridhar KS, Balkany TJ, et al. Effects of cis-platinum chemotherapy on otoacoustic emissions: the development of an objective screening protocol. Otolaryngol Head Neck Surg 1999; 121: 693-701.
26. Beck A, Maurer J, Welkoborsky HJ, Mann W,. Changes in transitory evoked otoacoustic emissions in chemotherapy and with cisplatin and 5FU. HNO 1992; 40: 123-127.
27. Allen GC, Tiu C, Koike K, et al. Transient-evoked otoacoustic emissions in children after cisplatin chemotherapy. Otolaryngol Head Neck Surg 1998; 118: 584-588. (Pubitemid 28222198)
28. Chang KW, Vohr BR, Norton SJ, Lekas MD,. External and middle ear status related to evoked otoacoustic emission in neonates. Arch Otolaryngol Head Neck Surg 1993; 119: 276-282. (Pubitemid 23072618)
29. Owens JJ, McCoy MJ, Lonsbury-Martin BL, Martin GK,. Otoacoustic emissions in children with normal ears, middle ear dysfunction, and ventilating tubes. Am J Otol 1993; 14: 34-40. (Pubitemid 23037490)
30. American Speech-Language-Hearing Association. Guidelines for the audiologic management of individuals receiving cochleotoxic drug therapy. ASHA 1994; 36 (suppl 12): 11-19.
31. Lewis MJ, DuBois SG, Fligor B, et al. Ototoxicity in children treated for osteosarcoma. Pediatr Blood Cancer 2009; 52: 387-391.
32. Yoshinaga-Itano C,. Benefits of early intervention for children with hearing loss. Otolaryngol Clin North Am 1999; 32: 1089-1102. (Pubitemid 29534050)
33. Moeller MP, Tomblin JB, Yoshinaga-Itano C, Connor CM, Jerger S,. Current state of knowledge: language and literacy of children with hearing impairment. Ear Hear 2007; 28: 740-753. (Pubitemid 350059317)
34. Blakley BW, Cohen JI, Doolittle ND, et al. Strategies for prevention of toxicity caused by platinum-based chemotherapy: review and summary of the annual meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, March 10, 2001. Laryngoscope 2002; 112: 1997-2001. (Pubitemid 35283462)
35. Campbell KCM, Meech RP, Rybak LP, Hughes LP,. D-methionine protects against cisplatin damage to the stria vascularis. Hear Res 1999; 138: 13-28.
36. Neuwelt EA, Brummett RE, Doolittle ND, et al. First evidence of otoprotection against carboplatin induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. J Pharmacol Exp Ther 1998; 286: 77-84. (Pubitemid 28317976)
37. Choe WT, Chinosornvatana N, Chang KW,. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol 2004; 25: 910-915. (Pubitemid 39491671)
38. Campbell KCM, Meech RP, Klemens JJ, Gerberi MT,. Prevention of noise- and drug-induced hearing loss with D-methionine. Hear Res 2007; 226: 92-103. (Pubitemid 46428036)
39. Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V,. Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res 2007; 226: 157-167. (Pubitemid 46428033)
40. Ross CJ, Katzov-Eckert H, Dube MP, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009; 41: 1345-1349.
41. Huang RS, Duan S, Shukla SJ, et al. Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 2007; 81: 427-437. (Pubitemid 47330203)